Remus PharmaceuticalsNSE:REMUS -1.02%55 ROE % is 11.85% as of Mar. 2026, which is 63% below its 10-year median of 31.70. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 115 Medical Distribution companies, Remus Pharmaceuticals ranks better than 73.04% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's ROE % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Remus Pharmaceuticals (NSE:REMUS) has a ROE % of 11.85% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Remus Pharmaceuticals and its competitors. This is 63% below median its historical median of 31.70. Over the past decade, Remus Pharmaceuticals' ROE % has ranged from 12.14 to 71.44. According to the industry distribution chart, Remus Pharmaceuticals ranks #31 out of 115 companies in the Medical Distribution industry, placing it in the top 27%.
Is Remus Pharmaceuticals' ROE % too high?
Remus Pharmaceuticals' current ROE % of 11.85% is 63% below median its 10-year median of 31.70. Over the past 10 years, this metric has ranged from a low of 12.14 to a high of 71.44. The Medical Distribution industry median ROE % is 7.10. Remus Pharmaceuticals' value of 11.85% is 66.9% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #31 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #31 out of 115 companies for ROE %. This puts Remus Pharmaceuticals in the upper half of its industry. The industry median ROE % is 7.10. Remus Pharmaceuticals' value of 11.85% is 66.9% above this benchmark. Historically, Remus Pharmaceuticals' own ROE % has ranged from 12.14 to 71.44 over the past decade. While the company's 10-year median is 31.70 vs. the industry median of 7.10, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current ROE % of 11.85% is 66.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current ROE % is 11.85%, which is 63% below median its own 10-year median of 31.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current ROE % is 11.85%, which is 63% below median its 10-year median of 31.70 and 66.9% above the Medical Distribution industry median of 7.10. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current ROE % is 11.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
ROE %: 11.85% (63% below median its 10-year median of 31.70)
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
Industry Position: 66.9% above the Medical Distribution median (#31 of 115)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
